Last reviewed 2026-04-20 · How we verify

Sinseron (INDISETRON)

Phase 2 active Small molecule

Sinseron (generic name: INDISETRON) is a indisetron drug. It is currently in Phase 2 development.

Sinseron works by binding to the 5-hydroxytryptamine receptor 3A, which is involved in various physiological processes.

Sinseron (INDISETRON) is a small molecule drug that targets the 5-hydroxytryptamine receptor 3A. It is classified as an indisetron and works by modulating serotonin receptors in the body. However, due to the lack of available information, its commercial status, approved indications, and key safety considerations are unknown. Further research is needed to determine its potential as a therapeutic agent. As a result, its current status in the pharmaceutical market remains unclear.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	INDISETRON
Drug class	indisetron
Target	5-hydroxytryptamine receptor 3A
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain has a special messenger system that uses serotonin to send signals. Sinseron helps regulate this system by blocking or enhancing the activity of serotonin receptors, which can affect mood, appetite, and other functions. By doing so, it may help alleviate symptoms associated with certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sinseron CI brief — competitive landscape report
Sinseron updates RSS · CI watch RSS

Frequently asked questions about Sinseron

What is Sinseron?

Sinseron (INDISETRON) is a indisetron drug.

How does Sinseron work?

Sinseron works by binding to the 5-hydroxytryptamine receptor 3A, which is involved in various physiological processes.

What is the generic name of Sinseron?

INDISETRON is the generic (nonproprietary) name of Sinseron.

What drug class is Sinseron in?

Sinseron belongs to the indisetron class. See all indisetron drugs at /class/indisetron.

What development phase is Sinseron in?

Sinseron is in Phase 2.

What does Sinseron target?

Sinseron targets 5-hydroxytryptamine receptor 3A and is a indisetron.

Drug class: All indisetron drugs
Target: All drugs targeting 5-hydroxytryptamine receptor 3A
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing